Major Depressive Disorder Treatment Market Is Estimated To Witness Moderate Growth
Major depressive disorder, also known as clinical depression or unipolar depression, is a mood disorder that causes a persistent feeling of sadness and loss of interest. Treatments for major depressive disorder include antidepressants such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors. These help improve symptoms such as depressed mood, lack of interest, changes in appetite or sleep, feelings of guilt or low self-worth, poor concentration, and thoughts of death or suicide.
The Major Depressive Disorder Treatment Market is estimated to be valued at US$ 11.83 Bn in 2023 and is expected to exhibit a CAGR of 2.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
There is an increasing adoption of non-invasive therapies for the treatment of major depressive disorder. Non-invasive therapies involve the use of technologies that do not require surgery or medication intake. These include repetitive transcranial magnetic stimulation (rTMS) therapy and electroconvulsive therapy (ECT). rTMS therapy uses magnetic fields to stimulate nerve cells in the parts of the brain linked with mood. ECT passes small electric currents through the brain, intentionally triggering a brief seizure. Both rTMS therapy and ECT have shown promising results in alleviating symptoms of depression and are emerging as a viable alternative to antidepressant medications. Their non-invasive nature and comparable efficacy to antidepressants is expected to drive their increasing adoption among depressed patients in the near future.
Porter's Analysis
Threat of new entrants: Low entry barriers and high development costs restrain new companies from entering the market.
Bargaining power of buyers: Large customer base enables buyers to negotiate for lower prices and favorable terms.
Bargaining power of suppliers: Established distribution channels and a few raw material suppliers limit their bargaining power.
Threat of new substitutes: Alternative therapies have low adopting rate due to efficacy and safety concerns.
Competitive rivalry: Companies compete on drug pricing and portfolio to gain higher market share.
SWOT Analysis
Strengths: Strong R&D capabilities and robust product portfolios of leading players.
Weaknesses: High capital requirement and costs associated with new drug development and clinical trials. Compliance with stringent regulations increases costs.
Opportunities: Rising awareness about mental health issues and increasing healthcare expenditure in developing nations offer growth prospects.
Threats: Patent expiries of blockbuster drugs and risk of drug failure during clinical trials hamper market revenues.
Key Takeaways
The Global Major Depressive Disorder Treatment Market Growth is expected to witness high, exhibiting CAGR of 2.8% over the forecast period, due to increasing awareness about mental health issues.
Regionally, North America dominated the market accounting for over 40% market share in 2023 due to supportive reimbursement policies and developed healthcare infrastructure in the region. Asia Pacific is anticipated to be the fastest growing region during the forecast period owing to rising medical tourism, increasing healthcare expenditure and growing prevalence of depression.
Key players operating in the major depressive disorder treatment market are Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, and GlaxoSmithKline plc. Key players are focused on increasing their product offerings through mergers, acquisitions and partnerships to strengthen their market position.
Explorer more information on this topic, Please visit -